GALAPAGOS NV/S (NASDAQ:GLPG) Price Target Raised to $171.00

GALAPAGOS NV/S (NASDAQ:GLPG) had its price objective lifted by Royal Bank of Canada to $171.00 in a research report released on Monday, The Fly reports.

Several other research analysts have also issued reports on GLPG. Cowen reissued a buy rating on shares of GALAPAGOS NV/S in a research report on Friday, July 26th. Stifel Nicolaus increased their price target on shares of GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a buy rating in a research report on Monday, July 15th. HC Wainwright increased their price target on shares of GALAPAGOS NV/S from $150.00 to $205.00 and gave the stock a buy rating in a research report on Monday, July 15th. Cantor Fitzgerald reissued a buy rating and issued a $130.00 price target on shares of GALAPAGOS NV/S in a research report on Thursday, May 2nd. Finally, Credit Suisse Group reissued an outperform rating on shares of GALAPAGOS NV/S in a research report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $156.45.

Shares of GLPG traded down $1.25 during trading hours on Monday, reaching $172.98. 2,015 shares of the company traded hands, compared to its average volume of 326,657. The firm has a fifty day moving average of $148.13. The firm has a market cap of $8.93 billion, a PE ratio of -262.26 and a beta of 1.54. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02. GALAPAGOS NV/S has a 1-year low of $85.00 and a 1-year high of $191.63.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GLPG. Bessemer Group Inc. bought a new stake in shares of GALAPAGOS NV/S during the second quarter valued at approximately $48,447,000. FMR LLC grew its stake in shares of GALAPAGOS NV/S by 35.3% during the first quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock valued at $59,148,000 after purchasing an additional 131,119 shares during the last quarter. Norges Bank bought a new stake in shares of GALAPAGOS NV/S during the fourth quarter valued at approximately $6,422,000. D. E. Shaw & Co. Inc. grew its stake in shares of GALAPAGOS NV/S by 354.6% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,093 shares of the biotechnology company’s stock valued at $1,752,000 after purchasing an additional 14,893 shares during the last quarter. Finally, Marshall Wace North America L.P. grew its stake in shares of GALAPAGOS NV/S by 149.4% during the first quarter. Marshall Wace North America L.P. now owns 18,751 shares of the biotechnology company’s stock valued at $2,208,000 after purchasing an additional 11,233 shares during the last quarter. 17.04% of the stock is currently owned by institutional investors and hedge funds.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Featured Article: Consumer behavior in bull markets

The Fly

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.